麻豆传媒

Jeff Minerd

Jeff Minerd

Authors >

Jeff Minerd

Jeff Minerd has been a medical and science writer for more than two decades, for organizations and publications including the National Institutes of Health (NIAID), The Infectious Diseases Society of America, The Cardiometabolic Health Congress, The Futurist Magazine, and The Scientist magazine. He received an Outstanding Contribution Award from the National Institute of Allergy and Infectious Diseases for the booklet Understanding Vaccines. He is also winner of the F. Scott Fitzgerald Short Story Prize.

Connect:

email image

Latest from Jeff Minerd

Lisa Carey, MD, on Cardiovascular Risk in Breast Cancer Survivors

Monitoring for long-term risk from treatment is important

Iain Timmins, PhD, on Physical Activity and Premenopausal Breast Cancer

Large cohort study provided solid evidence for risk reduction

A computer rendering of a transparent body with inflamed intestines highlighted.

Top-Down Treatment Superior to Step-Up Approach for Crohn's Disease

Early intensive treatment should be standard for most patients, researchers argue

Fardeen Bhimani, MD, on a Portable Breast Cancer 'Prescreening' Device for Resource-Limited Areas

Hand-held "Intelligent Breast Exam" can find tumors as small as 0.5 cm

Naveen Vasudev, MD, on Modified Dosing of Ipilimumab in Advanced RCC

Phase II trial suggested a less-intensive schedule was effective

A photo of a surgeon opening a plastic bag containing a donor liver.

Stigmatizing Language Common on Liver Transplant Websites

Researchers searched for terms including "alcoholic," "alcoholism," and "alcohol abuse"

John Boyages, MD, PhD, on Breast Cancer-Related Lymphedema

Data from PREVENT allowed more precise risk assessment

A computer rendering of a diseased liver.

Undiagnosed Liver Disease May Be Common in Patients With Dementia

Hepatic encephalopathy could be contributing to cognitive symptoms, study suggested

SCCM over a photo of Phoenix Convention Center, Phoenix, AZ

Effective Treatments Identified for Pediatric Complication of COVID

RECOVERY trial evaluated immunomodulatory therapy and corticosteroids

Matthew Galsky, MD, on PARP Inhibitors in Urothelial Cancer

Researchers seek to identify patients with targetable DDR mutations

5

鈥�